An open-label, dose-escalation (phase Ia) and expansion study (phase Ib) evaluated the safety and efficacy of the camrelizumab, an anti-PD-1 mAb, and apatinib combination therapy in advanced HCC patients (NCT02942329). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.